Genetics, Vol. 156, 963-972, November 2000, Copyright © 2000

A Genetic Analysis of Glucocorticoid Receptor Signaling: Identification and Characterization of Ligand-Effect Modulators in Saccharomyces cerevisiae

Raquel Sitcherana, Roger Emterb, Anastasia Krallib, and Keith R. Yamamotoa
a Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California 91413-0450
b Division of Biochemistry, Biozentrum, University of Basel, Basel CH4056, Switzerland

Corresponding author: Keith R. Yamamoto, Department of Cellular and Molecular Pharmacology, University of California, 513 Parnassus Ave., Box 0450, HSW 1201F, San Francisco, CA 94143-0450., yamamoto{at}cgl.ucsf.edu (E-mail)

Communicating editor: A. P. MITCHELL


*  ABSTRACT
*TOP
*ABSTRACT
*MATERIALS AND METHODS
*RESULTS
*DISCUSSION
*LITERATURE CITED

To find novel components in the glucocorticoid signal transduction pathway, we performed a yeast genetic screen to identify ligand-effect modulators (LEMs), proteins that modulate the cellular response to hormone. We isolated several mutants that conferred increased glucocorticoid receptor (GR) activity in response to dexamethasone and analyzed two of them in detail. These studies identify two genes, LEM3 and LEM4, which correspond to YNL323w and ERG6, respectively. LEM3 is a putative transmembrane protein of unknown function, and ERG6 is a methyltransferase in the ergosterol biosynthetic pathway. Analysis of null mutants indicates that LEM3 and ERG6 act at different steps in the GR signal transduction pathway.


THE glucocorticoid receptor (GR) is a ligand-dependent transcriptional regulator that mediates a panoply of developmental, physiological, and behavioral processes (TRONCHE et al. 1998 Down). GR integrates, coordinates, and responds to numerous cellular signals to accomplish its diverse functions. Regulation of glucocorticoid-responsive genes is a multistep process (BEATO et al. 1996 Down; YAMAMOTO 1997 Down). In the absence of hormone, the inactive apo-GR resides in the cytoplasm in association with molecular chaperones that maintain the aporeceptor in a high-affinity hormone-binding state. Hormone binding provokes dissociation of the chaperone machinery and nuclear translocation of the hormone-receptor complex. Once in the nucleus, GR binds selectively to specific genomic sites [glucocorticoid response elements (GREs)] and positively or negatively regulates transcription from nearby promoters (YAMAMOTO 1985 Down). GR is composed of three modular domains that harbor distinct, separable functions (see Fig 3A). The N terminus contains sequences responsible for transcriptional activation, repression, and synergy control. The central domain mediates Zn2+ interaction, dimerization, DNA binding, and nuclear localization. The C terminus interacts with molecular chaperones, coactivators, and hormone, and contains nuclear import and export sequences (PICARD and YAMAMOTO 1987 Down; WRIGHT et al. 1993 Down; INIGUEZ-LLUHI et al. 1997 Down).



View larger version (41K):
In this window
In a new window
Download PPT slide
 
Figure 1. Screen in yeast for ligand-effect modulators (LEMs). (A) Schematic of lem screen. YNK420 cells containing the GRE-lacZ reporter (p{Delta}S26X) and pRS314-N795 were UV- or EMS-mutagenized and plated on selective media (-trp, -ura, -his, +300 nM dex, +100 µg/ml 3-AT). Under these conditions, only mutants with increased GR activity were able to grow. GR activity was quantitated by assaying GRE-lacZ reporter gene response. (B) Phenotypes of representative lem mutants. Liquid ß-gal assays were performed on lysates from wild-type and mutant cells carrying full-length GR and GRE-lacZ, and grown in the absence or presence of 300 nm dex.



View larger version (20K):
In this window
In a new window
Download PPT slide
 
Figure 2. Phenotype of lem3 and lem4 mutants. (A) Western blot of whole-cell extract (40 ng of protein) from wild-type, lem3, and lem4 strains, detecting GR using the BuGR2 monoclonal antibody. (B) Dex dose-response curve: lem3 affects both GR potency and efficacy while lem4 affects potency.



View larger version (27K):
In this window
In a new window
Download PPT slide
 
Figure 3. Phenotypes of lem3 and lem4 mutants involve different GR domains. (A) Schematic of glucocorticoid receptor functional domains. Enh2/AF1 is the N-terminal regulatory domain that harbors activation, repression, and synergy functions. The ZFR contains zinc-binding, dimerization, DNA-binding, and nuclear localization sequences. The signaling domain is responsible for hormone binding, chaperone interaction, nuclear translocation, and transcriptional activation. (B) The activity of pG1-407C in response to 1 µM dex. (C) lem4 but not lem3 requires the GR-LBD. pRS314-N525 activity is increased in lem3 but remains unchanged in lem4 compared to wild type. (D) In vivo hormone-binding assay. Cells expressing pG1-F620S were grown in the absence or presence of 3H-dex and bound hormone was quantitated by liquid scintillation. Significantly increased hormone occupancy by GR is seen in the lem4 but not the lem3 mutant.

GR is not the sole determinant of the cellular response to ligands; other cellular factors are known to modulate GR action. For example, hormone transporters (KRALLI et al. 1995 Down; MAHE et al. 1996 Down), molecular chaperones (PICARD et al. 1990 Down; BOHEN and YAMAMOTO 1994 Down), chromatin remodeling factors (YOSHINAGA et al. 1992 Down; FRYER and ARCHER 1998 Down), coactivators (GLASS et al. 1997 Down), as well as other transcription factors such as AP-1 (MINER et al. 1991 Down) interact with GR and affect its function. The fact that hormone-dependent transcriptional activation by mammalian GR can be recapitulated in yeast (SCHENA and YAMAMOTO 1988 Down; GARABEDIAN and YAMAMOTO 1992 Down), an organism that lacks the entire intracellular receptor gene superfamily, suggests strongly that the GR signal transduction pathway evolved from pre-existing highly conserved components. Thus, given the ease of genetic manipulation and cloning in Saccharomyces cerevisiae, this heterologous species has proved advantageous for investigations of various factors in the GR signal transduction pathway (BOHEN and YAMAMOTO 1993 Down; KRALLI et al. 1995 Down; IMHOF and MCDONNELL 1996 Down; HONG et al. 1997 Down; INIGUEZ-LLUHI et al. 1997 Down; KRSTIC et al. 1997 Down).

Whereas most prior genetic studies of the glucocorticoid receptor signaling pathway have analyzed candidate genes, here we carried out an unbiased genetic screen to identify factors that can potentially act at any step in the GR signal transduction pathway. For this, we have taken advantage of the weak potency of the synthetic glucocorticoid dexamethasone (dex) in yeast to screen for factors that modulate hormone responses. We anticipated that some of these modulators could be functionally homologous to factors that impart the highly distinct, context-dependent GR responses observed in mammalian cells (CASOLINI et al. 1993 Down; KAVELAARS et al. 1995 Down; BAMBERGER et al. 1996 Down; LIM-TIO et al. 1997 Down; MCCORMICK et al. 1998 Down). In an earlier study (KRALLI et al. 1995 Down), we identified PDR5/LEM1, an ABC transporter that selectively exports ligands such as dex out of cells. Although the potency of dex in a pdr5{Delta} strain is ~10-fold greater than in wild-type cells, it is still weak when compared to other glucocorticoid agonists in yeast and far below its potency in animal cells (A. KRALLI, unpublished results). These observations suggest that factors in addition to PDR5 determine hormone responsiveness in yeast. To identify these factors, we extended our initial screen with two modifications: first, we devised a selection scheme and second, we isolated lem mutants in a pdr5{Delta} strain to preclude obtaining mutants affecting PDR5 function.


*  MATERIALS AND METHODS
*TOP
*ABSTRACT
*MATERIALS AND METHODS
*RESULTS
*DISCUSSION
*LITERATURE CITED

Yeast strains:
Yeast strains used in this study are isogenic derivatives of YPH499/500 (ura3-52 lys2-801 ade2-101 trp1-{Delta}63 his3-{Delta}200 leu2-{Delta}1). YNK420 was derived from YPH499 in two steps. First, the PDR5 locus was disrupted with the LEU2 gene using the DNA insert of plasmid pTCA/lem1::LEU2 (KRALLI et al. 1995 Down). Next, cells were transformed with pRS314-N795 and the KpnI fragment from p314-3TAT-C-His3. Trp+ transformants that had integrated the GRE-HIS3 reporter displayed hormone-dependent growth on SD -histidine. YNK425 is a Leu+, hormone-dependent His+ segregant from the cross of YNK420 to YPH500. To create the integrated GRE-CAN1 strain (YNK508), YNK410 cells were transformed with pRS314 and the EcoRI-PstI fragment from ptGT3c-Can1. Trp+ transformants were replica plated onto SD -arg + 50 µg/ml canavanine medium to select for canavanine-resistant (CanR) colonies. Twelve CanR isolates were further characterized. Upon introduction of GR expression plasmids, all were CanR in the absence of hormone and canavanine sensitive at high concentrations of agonist ligand. YRS350 and YNK558 are Lem- Leu- CanR segregants from crosses of YRS301 and YRS401 to YNK508, respectively. The Lem- phenotype was determined by assaying GR activity at 1 and 10 µM dex. Canavanine resistance was determined by checking for growth in the presence of 50 µg/ml canavanine.

Disruptions of LEM3 and ERG6 were generated in diploid strains using PCR-mediated gene targeting (WACH et al. 1994 Down). For the LEM3 disruption (YNK760), oligos lem3-5UT (GTG TCCTTTTAGAAATACGAGAGGGTGGTAAAATATTGAAGA GGTCGACGGTACCCC) and lem3-3UT (AAATTTTACAGGG TTAAAAATAAAGAAAACCATCACTCATCGATGAATTCGAGCTCG) were used to amplify a DNA fragment containing the kanMX resistance marker flanked by 42 nucleotides (nt) of 5' and 41 nt of 3' untranslated (UT) LEM3 DNA sequence. Following transformation with the lem3::kanMX DNA fragment, integration events were selected by isolating kanamycin-resistant (KanR) colonies [growth in the presence of 200 g/ml Geneticin (GIBCO)] and confirmed by PCR analysis of genomic DNA. For the disruption of ERG6 (YNK597), oligonucleotides erg6-1s (TATATAGTTCGGGTGTTTTCTCCTACCTCTGCTGCTCTCGAATTCCCGGGGATCCGG) and erg6-2a (GCATCGGACAGTCTGTTTGTAAGGCCTGCTAGCAATGAACGAAGCTAGCTTGGCTGCAG) were used to amplify the HIS3 gene flanked by ERG6 sequence from the YDp-H plasmid (BERBEN et al. 1991 Down). Following transformation with the erg6::HIS3 fragment, integration events were selected by growth in the absence of histidine and confirmed by PCR analysis of genomic DNA. YNK598 is a His+ KanR meiotic segregant generated from a cross of YNK761 to YNK597.

Plasmids:
pRS314-N795, pRS314-N525, pL2G-407C, pG1-F620S, and p{Delta}S26X were all described previously (SCHENA and YAMAMOTO 1988 Down; GARABEDIAN and YAMAMOTO 1992 Down). The p314-3TAT-C-His3 integration construct (gift of J. Iñiguez-Lluhí) contains a 5' KpnI-EcoRI HIS3 fragment followed by three glucocorticoid response elements from the tyrosine amino-transferase 3 gene (TAT3) and the entire HIS3-coding sequence. The ptGT3C-Can1 integration construct contains the following integration cassette: 833 bp of CAN1 5' UT sequence followed by the yeast phosphoglycerate kinase terminator, three glucocorticoid response elements from TAT3 (SCHENA and YAMAMOTO 1988 Down), the CYC1 promoter, and the first 822 nt of the CAN1-coding sequence. pRS316-LEM3 contains a PmlI-XbaI LEM3-containing fragment cloned into HindIII-XbaI of pRS316. pRS306-ERG6 and pRS316-ERG6 were made by subcloning an ERG6-containing NheI-EcoRI fragment into the XbaI-EcoRI sites of pRS306 and pRS316, respectively.

Yeast methods:
With the exception of lem4/erg6 cells, yeast transformations were carried out using lithium-acetate protocols (GIETZ et al. 1995 Down; AGATEP et al. 1998 Down). Mutant erg6 cells were transformed by electroporation (AUSUBEL et al. 1994 Down). Briefly, cells were grown and harvested as described in the lithium-acetate protocol. Following a 1-hr incubation in 100 mM Tris, pH 7.5, 1 mM EDTA, pH 8, 10 mM dithiotreitol, and 100 mM LiOAc, cells were washed in ddH2O, then in 1 M sorbitol, and resuspended in 1 ml ice-cold sorbitol to a cell density of 1010 cells/ml. A total of 50 µl of competent cells were added to 200 ng of transforming DNA and pulsed in a 0.2 cm-gap electroporation cuvette at 1.5 kV, 25 µF, and 200 {Omega}. Cells were allowed to recover for 1 hr in 1 ml of YEPD + 1 M sorbitol, resuspended in 1 M sorbitol, and spread onto SD medium + 1 M sorbitol lacking the appropriate amino acids.

Plate ß-galactosidase (ß-gal) assays were carried out by replica-plating yeast colonies or patches onto the appropriate SD medium in the absence or presence of hormone and growing overnight at 30°. Cells were overlaid with 0.5% agarose, 0.5 M NaPO4 (pH 7), 0.1% SDS, 2% N,N-dimethylformamide, and 0.05% 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-Gal) and incubated at room temperature for color development. Liquid ß-gal assays were carried out in 96-well microtiter plates as described previously (INIGUEZ-LLUHI et al. 1997 Down). Briefly, cells were grown to saturation at 30°, diluted 1:25 in the absence or presence of dex, and grown for 12–14 hr until cells were at OD650 0.2–0.4. A total of 10 µl of cells were permeabilized for 5 min at 25° with 10 µl of 2x Z buffer (120 mM NaPO4, pH 7.0, 10 mM KCl, 1 mM MgSO4, and 20 mM ß-mercaptoethanol) containing 5% CHAPS, and reactions were initiated by adding 180 µl of 0.5 mM chlorophenol red-ß-D-galactopyranoside (Boehringer Mannheim, Indianapolis, IN) in 1x Z buffer. Activity units were derived from the following equation: A = .

Mutagenesis, selection, and isolation of lem mutants:
YNK420 was transformed with pRS314-N795 and p{Delta}S26X. For UV mutagenesis, cells were exposed to UV light for 20 or 25 sec, resulting in 43 and 28% cell survival, respectively. Mutants were then plated at a density of 4.35 x 104 on SD -his -trp -ura plates containing 25 µg/ml 3-amino-triazole (3-AT) to suppress leaky HIS expression. For EMS mutagenesis, cells were treated with 0.03% EMS for 10 or 20 min, resulting in 50 and 25% survival, respectively. Approximately 104 survivors were plated on selective medium. UV- and EMS-induced mutants that grew over a period of 1–3 days were picked, restreaked to isolate single colonies, and assayed for GRE-lacZ activity by plate as well as liquid culture assays. RE and RU refer to EMS- and UV-induced mutations, respectively.

Genetic analyses:
lem mutants (RE10, RE21, RE41, RU41, RU48, RU68, RU91, and RU97) were crossed to YNK425 and GRE-lacZ activity was assayed in the heterozygous diploid. The RE10/WT diploid displayed increased GR activity, comparable to that of the RE10 haploid (data not shown). The remaining lem/WT diploids all had wild-type phenotypes. We sporulated RE41, RU48, RU68, and RU97 diploids and performed tetrad dissections and analyses. Wild-type and mutant phenotypes segregated 2:2 in four to eight complete tetrads. From these tetrads we isolated lem mutants of opposite mating types to generate crosses for complementation studies. As RE41/RU48, RE41/RU97, RU48/RU97, RU68/RE41, RU68/RU48, and RU68/RU97 heterozygous diploids all displayed wild-type GR activity at 1 µM dex, we concluded that they comprise four complementation groups. We backcrossed RU97/lem3 and RU48/lem4/erg6 to YNK425 once more and then crossed to YNK508. After sporulation and tetrad analysis, we isolated Lem- Leu- CanS tetrads to proceed with the cloning of the wild-type alleles.

Western blot analysis:
lem mutant and wild-type cells were grown to OD600 0.6–0.8 in 10-ml cultures. Cells were harvested, washed with H2O and 1 ml of high salt extraction buffer (400 mM NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.1% Triton X-100, 1 mM DTT, 1 mM PMSF, and 1 µg/ml aprotinin, leupeptin, and pepstatin A), and resuspended in 200 µl of high salt extraction buffer. An equal volume of glass beads was added and samples were shaken for 20 min at 4°. Extracts were collected and centrifuged at 14,000 x g for 10 min to separate insoluble material. Supernatants were transferred to a new tube and protein concentrations (8–15 µg/µl) were determined using the Bio-Rad protein assay. Samples were used immediately or frozen in liquid nitrogen and stored at -80° until use. Forty nanograms of total protein was run on a 7.5% SDS-PAGE gel and transferred onto nitrocellulose using a semidry gel blotter with transfer buffer (0.3% Tris, 1.12% glycine, 0.035% SDS, 20% methanol). Next, the membrane was incubated with 5% nonfat dry milk overnight at 4° in TBST (150 mM NaCl, 10 mM Tris (pH 7.5), and 0.05% Tween-20) and then with a 1:100 dilution of the primary GR antibody BuGR2 (GAMETCHU and HARRISON 1984 Down) in TBST for 1 hr at 25°. After three 10-min washes in TBST at room temperature, the membrane was incubated with a 1:4000 dilution of secondary antibody (goat anti-mouse IgG alkaline phosphatase conjugate) in TBST for 1 hr. The membrane was washed three times for 10 min with TBST and rinsed briefly with ddH2O. Signals were detected using Supersignal chemiluminescent substrate (Pierce Chemical, Rockford, IL).

In vivo hormone-binding assay:
The GR variant F620S displays increased hormone binding in yeast and is therefore more amenable for such studies (GARABEDIAN and YAMAMOTO 1992 Down). lem3-1 and erg6-101 have similar effects on wild-type GR and F620S GR in yeast (data not shown). Overnight cultures of yeast cells expressing pG1-F602S were grown to saturation, diluted 1:5, and grown until OD600 = 0.4–0.5 (at least two doublings). 3H-dex (1–2 x 106 cpm/ml) minus or plus 150-fold excess of cold hormone was added to cells and cultures were incubated at 30° for 2 hr. Samples were put on ice, centrifuged at 14,000 x g for 5 min at 4°, washed three times with 1 ml of ice-cold PBS/2% glucose (w/v), and resuspended in 50 µl of PBS/2% glucose. The amount of bound 3H-dex was quantitated by liquid scintillation.

Canavanine-negative selection cloning strategy:
YRS350 (can1::GRE3-CAN1 lem3-1 pdr5::GRE-lacZ) was transformed with the CEN-ARS, LEU2-marked yeast genomic library, p366 (American Type Culture Collection, Rockville, MD), and 105 transformants were plated on SD -arg -trp -ura, 300 µM dex, and 100 µg/ml canavanine. A total of 545 canavanine-resistant (CanR) cells grew after 3 days at 30°. Since cells could evade hormone-induced toxicity by silencing GR activity or losing receptor expression (e.g., by acquiring TRP1 from the library at the expense of the TRP1-marked GR-expression plasmid), we checked that CanR cells were still able to respond to deoxycorticosterone (DOC), a potent GR ligand in yeast. Library DNAs from 26 colonies that contained active receptor and displayed wild-type phenotypes (CanR and low GRE-lacZ activity) were isolated. Southern blot analysis revealed that five clones corresponded to PDR5 and 21 clones contained common, overlapping, or identical sequences (data not shown). An XbaI-PmlI fragment containing only the YNL323w ORF present in the 21 clones was both necessary and sufficient to confer plasmid-dependent complementation (Fig 4C).




View larger version (53K):
In this window
In a new window
Download PPT slide
 
Figure 4. Cloning wild-type Lem alleles. (A) Schematic of canavanine-negative selection cloning strategy. GRE-lacZ and GRE-CAN1 reporter genes are integrated into the yeast genome. Cells were transformed with pRS314-GRN795 and the wild-type genomic yeast library p366. (B) Growth of wild-type and mutant cells in the absence and presence of canavanine and dex. The growth of lem3 is greatly compromised and lem4 completely fails to grow in the presence of 100 µg/ml canavanine and 3 µM dex. (C) Complementation of lem3 and lem4 by YNL323W and ERG6, respectively.

YNK558 was transformed with the URA-marked, CEN-ARS yeast genomic library Ycplac33 (gift of M. Hall) using electroporation, plated on SD -arg -trp -ura, 3 µM dex, 100 µg/ml canavanine, and 1 M sorbitol, and allowed to grow for 4–6 days at 30°. A total of 336 CanR colonies were picked from 7.5 x 104 Ura+ transformants. A total of 87 colonies displayed lacZ activity in the presence of 20 µM dex (indicating the presence of active GR). To select for loss of the URA marker, cells were grown in the presence of 1 µg/ml 5-fluoroorotic acid (5-FOA). Two of these colonies exhibited plasmid-dependent, wild-type GR activity at 1 µM dex. Plasmids were isolated from these colonies and reintroduced into lem4 cells to confirm their ability to decrease response to dex.


*  RESULTS
*TOP
*ABSTRACT
*MATERIALS AND METHODS
*RESULTS
*DISCUSSION
*LITERATURE CITED

Isolation of mutants with increased GR responses to ligand:
To identify proteins that modulate the response of GR to ligand, we looked for mutants with increased ligand responses. Our starting strain, YNK420, contained a GR expression vector and two reporter genes, GRE-HIS3 and GRE-lacZ. YNK420 is able to grow in the absence of histidine and exhibits robust ß-galactosidase activity when grown in the presence of 1 µM DOC, a potent GR ligand in yeast. In contrast, YNK420 is unable to grow in the presence of 300 nM dex on minimal medium lacking histidine and forms white colonies on 5-bromo-4-chloro-1-indolyl ß-D-galactosidase (X-gal) plates (Fig 1A). YNK420 cells were mutagenized by exposure to UV light or EMS to a survival of 25–50%. Mutants that grew in 300 nM dex in the absence of histidine were obtained at a frequency of 3 x 10-4.

His+ isolates were restreaked to single colonies, assayed for expression of the GRE-lacZ reporter in response to hormone, and grouped into phenotypic classes (MATERIALS AND METHODS). Of 156 mutants, 16 formed white colonies in the presence of dex and X-gal, suggesting that their His+ phenotypes were independent of GR. Forty mutants showed high GR activity both in the absence and in the presence of ligand; many of these likely reflect lesions in the GR gene that truncate the C-terminal hormone-binding/signaling domain, yielding fragments with constitutive activity (GODOWSKI et al. 1987 Down; SCHENA and YAMAMOTO 1988 Down). The remaining 100 mutants exhibited increased ligand-dependent ß-gal activity and thus met both criteria for increased GR activity in response to ligand. To determine whether the mutations were chromosomal or plasmid borne, we selected isolates that had lost the plasmids and retransformed with wild-type GR and reporter plasmids; 95% retained their ligand-dependent His+ LacZ+ phenotype. The phenotypes of 11 representative lem mutants are shown in Fig 1B.

Genetic analysis and characterization of lem mutants:
Eight lem mutants were backcrossed to wild-type strains, and GR activity was assayed in the heterozygous diploids to determine whether the mutations were dominant or recessive. One mutant (RE10) was dominant; the others (RE21, RE41, RU41, RU48, RU68, RU91, and RU97) were recessive (MATERIALS AND METHODS). We sporulated lem x wild-type diploids and analyzed tetrads from RE41, RU48, RU68, and RU97 crosses. In all cases, the mutant phenotypes segregated in a 2:2 ratio, indicating single-gene alterations. Complementation studies revealed that these mutants define four complementation groups (see MATERIALS AND METHODS).

We chose for further characterization two mutants with relatively pronounced phenotypes, RU97 and RU48. The mutants, renamed lem3-1 and lem4-101, respectively, also exhibited moderate growth defects. Western blots of whole-cell extracts using the GR-specific monoclonal antibody BuGR2 revealed similar levels of accumulated GR in the wild-type and mutant backgrounds (Fig 2A). Thus, lem3-1 and lem4-101 appear to affect the GR signaling pathway downstream of receptor expression.

We next performed hormone dose-response assays on lem3-1 and lem4-101 cultures. The results revealed that lem4-101 displayed increased ligand potency (responding to lower concentrations of dex) whereas receptor efficacy (maximal activation levels at saturating hormone conditions) was similar to that of the wild type (Fig 2B). In contrast, lem3-1 displayed marked increases in both potency and efficacy.

lem3 and lem4 affect different steps in the GR signal transduction pathway:
The dose-response assays implied that lem3 and lem4 affect different GR functions. Consistent with this view, we found that lem3 and lem4 require different segments of GR for their increased ligand responses. Thus, activity of the GR derivative 407C, which lacks the N-terminal domain, remained significantly increased in lem4 cells but was only weakly increased in lem3 cells (Fig 3A and Fig B). In contrast, the lem4 phenotype was lost in the absence of the GR-ligand-binding domain (LBD), whereas the effect of the lem3 mutation was retained on this truncated GR derivative GR-N525 (Fig 3A and Fig C).

The effect of lem4 on hormone potency, as well as the requirement of the GR-LBD for the lem4 phenotype, suggested that the lem4 mutant might increase hormone availability or binding to GR. We tested this by measuring intracellular hormone accumulation in vivo, which reflects GR occupancy by hormone. Indeed, binding of 3H-dex was increased 8- to 10-fold in lem4 relative to wild type. In contrast, lem3 displayed only a twofold increase in hormone binding in the presence of 1 µM dex (Fig 3D), which is clearly insufficient to account for the large increase in the transcriptional activity of full-length GR at the same hormone concentration (Fig 2B). Together, these results indicate that lem3 and lem4 affect distinct GR domains and likely different steps in GR signaling: the lem3-1 mutation appears to operate on the N-terminus/DNA-binding domain, whereas lem4-101 affects GR functions housed in the C terminus, such as ligand binding.

Cloning wild-type LEM genes:
To isolate the wild-type LEM alleles, we devised a negative selection scheme based on hormone-dependent expression of a toxic gene (Fig 4A). For this, the lem3 and lem4 mutations were introduced into a yeast strain that harbors two integrated GR-responsive reporters: GRE-lacZ and GRE-CAN1. CAN1, the yeast arginine permease, allows entry of the toxic arginine analog canavanine into yeast (BOLLER et al. 1975 Down). The lem3 and lem4 mutants (YRS350 and YNK558) thus fail to grow in the presence of dex and canavanine, in contrast to wild-type cells, which are canavanine resistant (Fig 4A).

To isolate LEM3, YRS350 was transformed with a low-copy LEU2 yeast genomic library and plated on medium lacking arginine and containing 300 nM dex and 100 µg/ml canavanine. Of 105 Leu+ transformants, 545 isolates were canavanine resistant. These were assayed for hormone-responsive lacZ expression in the presence of 1 µM dex and 10 µM DOC (see MATERIALS AND METHODS). Twenty-six isolates responded to the high concentration of DOC and displayed little response to the low concentration of dex, as expected for complementation of the lem3 defect to produce wild-type receptor activity. Library DNAs were purified and reintroduced into lem3 cells to confirm plasmid-dependent complementation (Fig 4B). As our lem3 strain lacks PDR5 (Table 1), we expected to recover both the PDR5 and LEM3 genes with our cloning strategy. Indeed, Southern blot analysis revealed that 5 clones contained PDR5; the remaining 21 clones contained inserts overlapping with each other but not with PDR5 (data not shown). Deletion analysis and sequencing revealed that YNL323w was both necessary and sufficient to complement lem3 (see MATERIALS AND METHODS).


 
View this table:
In this window
In a new window

 
Table 1. S. cerevisiae strains used in this study

To isolate LEM4, YNK558 was transformed with a low-copy URA3 yeast genomic library. Of 75,000 Ura+ transformants, 336 were canavanine resistant. Eighty-seven retained active GR (lacZ expression in the presence of 20 µM dex) and displayed wild-type transcriptional responses to dex (Fig 4B). After selection for loss of the URA3-marked library plasmids on 5-FOA plates, two isolates reverted to the Lem4- phenotype, indicating that complementation was plasmid dependent in those cells. Sequencing revealed that one plasmid carried the PDR5 gene; the other contained two fragments from two different chromosomes that coded for five complete open reading frames (ORFs). Deletion analysis and subcloning (see MATERIALS AND METHODS) showed the complementing ORF to be YML008c (ERG6).

To confirm that defects in YNL323w and ERG6 gave rise to the lem3 and lem4 mutants, respectively, we disrupted these genes in our YNK410 strain background (see MATERIALS AND METHODS). The resultant ynl323{Delta} and erg6{Delta} strains showed increased responses to hormone, parallel to those seen in the original lem3-1 and lem4-101 mutants. Notably, GR activity in lem3{Delta} was higher than in our lem3 mutant strain, suggesting that the null phenotype is more severe than that of the lem3-1 allele. Mating of ynl323w{Delta} and lem3-1 gave rise to a diploid with a Lem- phenotype, indicating that ynl323w and lem3-1 affect the same complementation group. Furthermore, in eight tetrads derived from the ynl323w{Delta} lem3-1 diploid, all segregants were Lem-. We concluded that YNL323 and LEM3 correspond to the same genetic locus. Thus, YNL323 was renamed LEM3. Similarly, the cross of the erg6{Delta} strain to a lem4-101 strain generated a diploid with a Lem4- phenotype (data not shown). Integration of an ERG6-containing DNA fragment from pRS303-ERG6 in a lem4-101 strain at the ERG6 locus restored wild-type GR activity. A cross of this strain to a wild-type strain yielded tetrads in which all segregants (95/95) exhibited wild-type response to hormone. Therefore, LEM4 and ERG6 are allelic. We shall refer to the lem4-101 strain as erg6-101.

Do lem3 and erg6 affect overlapping or independent regulatory pathways?
LEM3 is predicted to encode a novel 414-amino-acid protein of unknown function, bearing two putative transmembrane domains. ERG6 is a methyl transferase involved in ergosterol biosynthesis (XU and NES 1988 Down). lem3-1 and erg6-101 appear to affect receptor activity by different mechanisms (Fig 3). To infer whether lem3 and erg6 affect independent or overlapping genetic pathways, we tested the phenotype of a lem3{Delta} erg6{Delta} double mutant (YNK598, Fig 5C). The phenotypes of lem3{Delta} and erg6{Delta} were additive in the lem3{Delta} erg6{Delta} strain, suggesting that they affect different pathways. Taken together, our data suggest that LEM3 and LEM4/ERG6 are components of separate, independent pathways that downregulate GR function.



View larger version (23K):
In this window
In a new window
Download PPT slide
 
Figure 5. Lem3 and Lem4/Erg6 are part of independent signaling pathways. (A) Phenotypes of lem3-1 and lem3{Delta}. (B) Phenotypes of erg6-101 and erg6{Delta}. (C) GR activity in lem3{Delta} lem4{Delta} double-mutant cells. lem3{Delta} and lem4{Delta} phenotypes are additive.


*  DISCUSSION
*TOP
*ABSTRACT
*MATERIALS AND METHODS
*RESULTS
*DISCUSSION
*LITERATURE CITED

Identification of lems:
A previous unbiased screen for mutants that modulate GR activity revealed the yeast ABC transporter PDR5/LEM1. PDR5 affects GR activity by actively exporting particular ligands from cells, challenging the notion that transit of steroids across the plasma membrane occurs solely by passive diffusion (KRALLI et al. 1995 Down). To find additional ligand-effect modulators (LEMs), we devised a modified screen aimed at isolation of yeast mutants with increased response to dex. We performed the screen in a pdr5 null background to preclude identifying proteins in the Pdr5 pathway that regulate hormone export. Analysis of two mutants, lem3 and lem4, indicated that they negatively regulate GR activity in a Pdr5+ cell. Genetic tests on four mutants revealed four complementation groups, indicating that there are many such modulators in yeast (and presumably in mammalian cells) and that this screen is far from saturated.

Lem3 and Lem4/Erg6 affect different GR activities:
Characterization of two mutants, lem3 and lem4/erg6, suggested that they affect GR activity at distinct steps, as analyses of various GR derivatives revealed that they operate primarily on different GR domains. Consistent with this view, the erg6-101 but not the lem3-1 mutation significantly increases hormone occupancy of GR in vivo. GR activity in both lem3 and lem4 mutant cells is increased in the presence of various ligands, such as dex, deoxycorticosterone, and corticosterone; moreover, lem3 confers increased activity on other intracellular receptors, including the progesterone, estrogen, and mineralocorticoid receptors.

LEM3 is predicted to encode a novel transmembrane protein of unknown function. It shares ~40% identity at the protein level with two predicted yeast membrane proteins of unknown function, CDC50 and YNR048w, as well as mammalian expressed sequence tags. We are currently determining whether GR activity is affected in CDC50 and YNR048w and whether the activity of other endogenous transcription factors is increased in the lem3 mutant. It is unlikely that LEM3 affects cellular hormone levels or binding of hormone by GR given that lem3 mutants affect the function of GR derivatives that lack the ligand binding domain. LEM3 is thus likely to affect a downstream step in the GR pathway, such as nuclear localization, DNA binding, or transcriptional activation.

ERG6 encodes the S-adenosylmethionine {Delta}-24-sterol-C-methyltransferase, which carries out side-chain methylation of zymosterol in the ergosterol biosynthesis pathway (GABER et al. 1989 Down; HARDWICK and PELHAM 1994 Down). Mutations in ERG6 lead to altered membrane sterol composition and a pleiotropic sensitivity to numerous structurally diverse compounds, such as cycloheximide, Brefeldin A, and nalidixic acid (WELIHINDA et al. 1994 Down; LEES et al. 1995 Down; PRENDERGAST et al. 1995 Down). How ERG6 and/or sterol composition affect sensitivity to drugs is not clear.

Given the increase in hormone-bound GR in erg6-101 cells, it seems plausible that the increased response to hormone results from higher intracellular hormone levels in these cells due to altered membrane composition. The identification of two genes, PDR5 and ERG6, that likely modulate hormone transport across the membrane implies that establishment or maintenance of GR function in yeast may depend on hormone accessibility. Moreover, they demonstrate that there are multiple cellular pathways that can affect hormone access to the receptor. Previous studies on GR signaling have focused primarily on the endpoint of regulation, transcription, as a way to achieve tissue specificity of glucocorticoids. Mechanisms that influence the intracellular concentration of steroid hormones may be a distinct and novel way to account for selective actions of intracellular receptors.

Implications for LEM functions:
Factors that modulate ligand responsiveness and/or ligand selectivity are likely to contribute to the context-specific actions of GR. For example, factors that catabolize ligand or sequester ligand partly explains why the mineralocorticoid receptor, which can bind with high affinity to both corticosterone and aldosterone, responds only to aldosterone in particular cells of the kidney (BENEDIKTSSON et al. 1995 Down; FUNDER 1997 Down). Furthermore, misregulation of a LEM could lead to aberrant responses of steroid receptors to their cognate ligands, such as hormone insensitivity or hypersensitivity, as is seen in several diseases and in therapeutic scenarios (BRONNEGARD et al. 1996 Down). Glucocorticoid resistance and hypersensitivity can arise in individuals bearing wild-type glucocorticoid receptor (ADCOCK et al. 1995 Down; BARNES and ADCOCK 1995 Down); similarly, patients who respond well to hormone therapy can suddenly acquire resistance (KLUMPER et al. 1995 Down; KAWA and THOMPSON 1996 Down; LAMBERTS 1996 Down).

Evolution of GR modulators:
As eukaryotes evolved into multicellular organisms, they built upon highly conserved regulatory mechanisms to achieve more diverse and complex cellular functions. The emergence of intracellular receptors as transcriptional regulators and small hydrophobic molecules as signaling factors in metazoans reflects the use of pre-existing cellular factors to achieve context-specific activities. This is exemplified by the ability of the glucocorticoid receptor to confer heterologous, ligand-dependent transcriptional activation in yeast. Although it is quite likely that some GR modulators will be unique to mammalian cells, to date, many yeast factors that affect GR function appear to have functional homologues in mammalian cells (BOHEN and YAMAMOTO 1993 Down; CAIRNS et al. 1996 Down; IMHOF and MCDONNELL 1996 Down). Thus, the genetic approach we present here is likely to provide new insight into the regulation of intracellular receptor function.


*  ACKNOWLEDGMENTS

We thank A. Stotz for technical assistance, J. Iñiguez-Lluhí for the p314-TAT3-C-His3 plasmid, M. Hall for the LEU2 library, members of the Yamamoto lab for helpful discussion, and I. Herskowitz for comments on the manuscript. This work was supported by a grant from National Science Foundation (K.R.Y.), the Swiss National Science Foundation (A.K.), and the Max Cloëtta Foundation (A.K.).

Manuscript received January 20, 2000; Accepted for publication July 10, 2000.


*  LITERATURE CITED
*TOP
*ABSTRACT
*MATERIALS AND METHODS
*RESULTS
*DISCUSSION
*LITERATURE CITED

ADCOCK, I. M., S. J. LANE, C. R. BROWN, T. H. LEE, and P. J. BARNES, 1995  Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J. Exp. Med. 182:1951-1958[Abstract/Free Full Text].

AGATEP, R., R. D. KIRKPATRICK, D. L. PARCHALIUK, R. A. WOODS and R. D. GEITZ, 1998 Transformation of Saccharomyces cerevisiae by the lithium acetate single-stranded carrier DNA/polyethylene glycol (LiAc/ss-DNA/PEG) protocol. Technical Tips Online.

AUSUBEL, F. M., R. BRENT, R. E. KINGSTON, D. D. MOORE, J. G. SEIDMAN et al., 1994 Electroporation of Yeast (Current Protocols in Molecular Biology). John Wiley & Sons, New York.

BAMBERGER, C. M., H. M. SCHULTE, and G. P. CHROUSOS, 1996  Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrine Rev. 17:245-261[Medline].

BARNES, P. J. and I. M. ADCOCK, 1995  Steroid resistance in asthma. Q. J. Med. 88:455-468.

BEATO, M., M. TRUSS, and S. CHÁVEZ, 1996  Control of transcription by steroid hormones. Ann. NY Acad. Sci. 784:93-123[Medline].

BENEDIKTSSON, R., B. R. WALKER, and C. R. EDWARDS, 1995  Cellular selectivity of aldosterone action: role of 11 beta-hydroxysteroid dehydrogenase. Curr. Opin. Nephrol. Hypertens. 4:41-46[Medline].

BERBEN, G., J. DUMONT, V. GILLIQUET, P. A. BOLLE, and F. HILGER, 1991  The YDp plasmids: a uniform set of vectors bearing versatile gene disruption cassettes for Saccharomyces cerevisiae.. Yeast 7:475-477[Medline].

BOHEN, S. P. and K. R. YAMAMOTO, 1993  Isolation of Hsp90 mutants by screening for decreased steroid receptor function. Proc. Natl. Acad. Sci. USA 90:11424-11428[Abstract/Free Full Text].

BOHEN, S. P., and K. R. YAMAMOTO, 1994 Modulation of steroid receptor signal transduction by heat shock proteins, pp. 313–334 in The Biology of Heat Shock Proteins and Molecular Chaperones, edited by R. I. MORIMOTO, A. TISSIÈRES and C. GEORGOPOULOS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

BOLLER, T., M. DÜRR, and A. WIEMKEN, 1975  Characterization of a specific transport system for arginine in isolated yeast vacuoles. Eur. J. Biochem. 54:81-91[Medline].

BRÖNNEGÅRD, M., P. STIERNA, and C. MARCUS, 1996  Glucocorticoid resistant syndromes—molecular basis and clinical presentations. J. Neuroendocrinol. 8:405-415[Medline].

CAIRNS, B. R., R. S. LEVINSON, K. R. YAMAMOTO, and R. D. KORNBERG, 1996  Essential role of Swp73p in the function of yeast Swi/Snf complex. Genes Dev. 10:2131-2144[Abstract/Free Full Text].

CASOLINI, P., P. V. PIAZZA, M. KABBAJ, F. LEPRAT, and L. ANGELUCCI et al., 1993  The mesolimbic dopaminergic system exerts an inhibitory influence on brain corticosteroid receptor affinities. Neuroscience 55:429-434[Medline].

EGNER, R., F. E. ROSENTHAL, A. KRALLI, D. SANGLARD, and K. KUCHER, 1998  Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter. Mol. Biol. Cell 9:523-543[Abstract/Free Full Text].

FRYER, C. J. and T. K. ARCHER, 1998  Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature 393:88-91[Medline].

FUNDER, J. W., 1997  Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu. Rev. Med. 48:231-240[Medline].

GABER, R. F., D. M. COPPLE, B. K. KENNEDY, M. VIDAL, and M. BARD, 1989  The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol. Mol. Cell. Biol. 9:3447-3456[Abstract/Free Full Text].

GAMETCHU, B. and R. W. HARRISON, 1984  Characterization of a monoclonal antibody to the rat liver glucocorticoid receptor. Endocrinology 114:274-279[Abstract].

GARABEDIAN, M. J. and K. R. YAMAMOTO, 1992  Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast. Mol. Biol. Cell 3:1245-1257[Abstract].

GIETZ, R. D., R. H. SCHIESTL, A. R. WILLEMS, and R. A. WOODS, 1995  Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 11:355-360[Medline].

GLASS, C. K., D. W. ROSE, and M. G. ROSENFELD, 1997  Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9:222-232[Medline].

GODOWSKI, P. J., S. RUSCONI, R. MIESFELD, and K. R. YAMAMOTO, 1987  Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement. Nature 325:365-368. (erratum: Nature 326: 105).[Medline].

HARDWICK, K. G. and H. R. PELHAM, 1994  SED6 is identical to ERG6, and encodes a putative methyltransferase required for ergosterol synthesis. Yeast 10:265-269[Medline].

HONG, H., K. KOHLI, M. J. GARABEDIAN, and M. R. STALLCUP, 1997  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol. 17:2735-2744[Abstract].

IMHOF, M. O. and D. P. MCDONNELL, 1996  Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol. Cell. Biol. 16:2594-2605[Abstract].

IGUEZ-LLUHÍ, J. A., D. Y. LOU, and K. R. YAMAMOTO, 1997  Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus. J. Biol. Chem. 272:4149-4156[Abstract/Free Full Text].

KAVELAARS, A., J. ZIJLSTRA, J. M. BAKKER, E. P. VAN REES, and G. H. VISSER et al., 1995  Increased dexamethasone sensitivity of neonatal leukocytes: different mechanisms of glucocorticoid inhibition of T cell proliferation in adult and neonatal cells. Eur. J. Immunol. 25:1346-1351[Medline].

KAWA, S. K. and E. B. THOMPSON, 1996  Lymphoid cell resistance to glucocorticoids in HIV infection. J. Steroid Biochem. Mol. Biol. 57:259-263[Medline].

KLUMPER, E., R. PIETERS, A. J. VEERMAN, D. R. HUISMANS, and A. H. LOONEN et al., 1995  In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86:3861-3868[Abstract/Free Full Text].

KRALLI, A., S. P. BOHEN, and K. R. YAMAMOTO, 1995  LEM1, an ATP-binding-cassette transporter, selectively modulates the biological potency of steroid hormones. Proc. Natl. Acad. Sci. USA 92:4701-4705[Abstract/Free Full Text].

KRSTIC, M. D., I. ROGATSKY, K. R. YAMAMOTO, and M. J. GARABEDIAN, 1997  Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol. Cell. Biol. 17:3947-3954[Abstract].

LAMBERTS, S. W., 1996  The glucocorticoid insensitivity syndrome. Hormone Res. 45(Suppl. 1):2-4.

LEES, N. D., B. SKAGGS, D. R. KIRSCH, and M. BARD, 1995  Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae—a review. Lipids 30:221-226[Medline].

LIM-TIO, S. S., M. C. KEIGHTLEY, and P. J. FULLER, 1997  Determinants of specificity of transactivation by the mineralocorticoid or glucocorticoid receptor. Endocrinology 138:2537-2543[Abstract/Free Full Text].

MAHÉ, Y., Y. LEMOINE, and K. KUCHLER, 1996  The ATP binding cassette transporters Pdr5 and Snq2 of Saccharomyces cerevisiae can mediate transport of steroids in vivo. J. Biol. Chem. 271:25167-25172[Abstract/Free Full Text].

MCCORMICK, J. A., V. LYONS, J. NOBLE, W. ESTER, and M. J. MEANEY et al., 1998  Tissue-specific differences in rat glucocorticoid receptor gene transcriptional regulation. Biochem. Soc. Trans. 26:S207[Medline].

MINER, J. N., M. I. DIAMOND, and K. R. YAMAMOTO, 1991  Joints in the regulatory lattice: composite regulation by steroid receptor-AP1 complexes. Cell Growth Differ. 2:525-530[Medline].

PICARD, D. and K. R. YAMAMOTO, 1987  Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J. 6:3333-3340[Medline].

PICARD, D., B. KHURSHEED, M. J. GARABEDIAN, M. G. FORTIN, and S. LINDQUIST et al., 1990  Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature 348:166-168[Medline].

PRENDERGAST, J. A., R. A. SINGER, N. ROWLEY, A. ROWLEY, and G. C. JOHNSTON et al., 1995  Mutations sensitizing yeast cells to the start inhibitor nalidixic acid. Yeast 11:537-547[Medline].

SCHENA, M. and K. R. YAMAMOTO, 1988  Mammalian glucocorticoid receptor derivatives enhance transcription in yeast. Science 241:965-967[Abstract/Free Full Text].

SIKORSKI, R. S. and P. HIETER, 1989  A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27[Abstract/Free Full Text].

TRONCHE, F., C. KELLENDONK, H. M. REICHARDT, and G. SCHÜTZ, 1998  Genetic dissection of glucocorticoid receptor function in mice. Curr. Opin. Genet. Dev. 8:532-538[Medline].

WACH, A., A. BRACHAT, R. PÖHLMANN, and P. PHILIPPSEN, 1994  New heterologous modules for classical or PCR-based gene disruptions in Saccharomyces cerevisiae.. Yeast 10:1793-1808[Medline].

WELIHINDA, A. A., A. D. BEAVIS, and R. J. TRUMBLY, 1994  Mutations in LIS1 (ERG6) gene confer increased sodium and lithium uptake in Saccharomyces cerevisiae.. Biochim. Biophys. Acta 1193:107-117[Medline].

WRIGHT, A. P., J. ZILLIACUS, I. J. MCEWAN, K. DAHLMAN-WRIGHT, and T. ALMLÖF et al., 1993  Structure and function of the glucocorticoid receptor. J. Steroid Biochem. Mol. Biol. 47:11-19[Medline].

XU, S. H. and W. D. NES, 1988  Biosynthesis of cholesterol in the yeast mutant erg6. Biochem. Biophys. Res. Commun. 155:509-517[Medline].

YAMAMOTO, K. R., 1985  Steroid receptor regulated transcription of specific genes and gene networks. Annu. Rev. Genet. 19:209-252[Medline].

YAMAMOTO, K. R., 1997  Multilayered control of intracellular receptor function. The Harvey Lectures 91:1-19.

YOSHINAGA, S. K., C. L. PETERSON, I. HERSKOWITZ, and K. R. YAMAMOTO, 1992  Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science 258:1598-1604[Abstract/Free Full Text].




This article has been cited by other articles:


Home page
Brief Funct Genomic ProteomicHome page
M. J. Osborn and J. R. Miller
Rescuing yeast mutants with human genes
Brief Funct Genomic Proteomic, August 13, 2007; (2007) elm017v1.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Ruegg, F. Holsboer, C. Turck, and T. Rein
Cofilin 1 Is Revealed as an Inhibitor of Glucocorticoid Receptor by Analysis of Hormone-Resistant Cells
Mol. Cell. Biol., November 1, 2004; 24(21): 9371 - 9382.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Kunz, R. Sandoval, P. Carlsson, J. Carlstedt-Duke, J. W. Bloom, and R. L. Miesfeld
Identification of a Novel Glucocorticoid Receptor Mutation in Budesonide-Resistant Human Bronchial Epithelial Cells
Mol. Endocrinol., December 1, 2003; 17(12): 2566 - 2582.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. K. Hanson, L. Malone, J. L. Birchmore, and J. W. Nichols
Lem3p Is Essential for the Uptake and Potency of Alkylphosphocholine Drugs, Edelfosine and Miltefosine
J. Biol. Chem., September 19, 2003; 278(38): 36041 - 36050.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. S. Gupta, V.-K. Ton, V. Beaudry, S. Rulli, K. Cunningham, and R. Rao
Antifungal Activity of Amiodarone Is Mediated by Disruption of Calcium Homeostasis
J. Biol. Chem., August 1, 2003; 278(31): 28831 - 28839.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
T. J. Begley, A. S. Rosenbach, T. Ideker, and L. D. Samson
Damage Recovery Pathways in Saccharomyces cerevisiae Revealed by Genomic Phenotyping and Interactome Mapping
Mol. Cancer Res., December 1, 2002; 1(2): 103 - 112.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. Kato, K. Emoto, C. Fredriksson, H. Nakamura, A. Ohta, T. Kobayashi, K. Murakami-Murofushi, T. Kobayashi, and M. Umeda
A Novel Membrane Protein, Ros3p, Is Required for Phospholipid Translocation across the Plasma Membrane in Saccharomyces cerevisiae
J. Biol. Chem., September 27, 2002; 277(40): 37855 - 37862.
[Abstract] [Full Text] [PDF]